8-K
filed May 13, 2024, 7:59 PM ET
ticker ZVRA
CIK 0001434647
other material
confidence high
sentiment negative
materiality 0.15
Zevra Therapeutics shareholders reject amendments to 2014 Equity Incentive Plan at annual meeting
ZEVRA THERAPEUTICS, INC.
- Three Class III directors elected: Thomas D. Anderson, Neil F. McFarlane, Alvin Shih, M.D.
- Shareholders ratified Ernst & Young LLP as independent auditor for FY2024.
- Advisory say-on-pay vote approved (11.2M for, 9.9M against).
- Proposal to amend 2014 Equity Incentive Plan failed: 4.1M for, 17.0M against, 9.9M broker non-votes.
- Approximately 74.5% of shares represented at the meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
ZEVRA THERAPEUTICS, INC. shareholders approved Election of Alvin Shih, M.D. as a Class III director at the 2024-05-13 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-13
Exact text from the filing
Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
ZEVRA THERAPEUTICS, INC. shareholders approved Election of Neil F. McFarlane as a Class III director at the 2024-05-13 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-13
Exact text from the filing
Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
ZEVRA THERAPEUTICS, INC. shareholders approved Election of Thomas D. Anderson as a Class III director at the 2024-05-13 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-13
Exact text from the filing
1. Election of Directors For Withheld Broker Non-Votes Thomas D. Anderson 15,266,761 6,062,268 9,865,186
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
ZEVRA THERAPEUTICS, INC. shareholders approved Advisory approval of compensation of named executive officers at the 2024-05-13 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-05-13
Exact text from the filing
3. Approval, on an advisory and non-binding basis, of the compensation of the Company's named executive officers. 11,167,215 9,888,153 273,661 9,865,186
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
ZEVRA THERAPEUTICS, INC. shareholders rejected Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan at the 2024-05-13 meeting.
- Proposal
- equity plan
- Outcome
- failed
- Meeting
- 2024-05-13
Exact text from the filing
4. Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan 4,143,728 16,964,060 221,241 9,865,186
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-13 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-13
Exact text from the filing
2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company ’ s fiscal year ending December 31, 2024. 22,543,306 7,352,086 1,298,823 —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.